Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective.

ABSTRACT:

Background

Clinical trials in China have demonstrated that ranibizumab can improve the clinical outcomes of branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). However, no economic evaluation of ranibizumab has been conducted among Chinese patient population.

Methods

To provide insights into the economic profile of ranibizumab among Chinese RVO population, a Markov state-transition model was used to predict the outcomes of ranibizumab comparing to laser photocoagulation and observational-only care from the societal perspective. This model simulated changes in patient visuality, quality-adjusted of life years (QALY), medical costs, and direct non-medical costs of individuals with visual impairment due to BRVO or CRVO in lifetime. The base-case anal

SUBMITTER: Ni W 

PROVIDER: S-EPMC8142632 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature